Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953131 · ClinicalTrials.gov registry record · Phase 1
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
A Phase 1 study of Meningioma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03953131 is a Phase 1 study of Meningioma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants, below the 99-participant average among 21 other Meningioma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03953131, a Phase 1 study of Meningioma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas. Giving Gallium Ga 68-DOTATATE before PET/CT scan may work better in predicting tumor growth in patients with meningiomas.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- RADIATION Gallium Ga 68-DOTATATE
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953131
The ClinicalTrials.gov registry entry for NCT03953131 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 21 other Meningioma trials with a reported enrollment target (87% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.
NCT03953131 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03953131 about?
NCT03953131 is a clinical study titled "Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas". This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas. Giving Gallium Ga 68-DOTATATE before PET/CT scan may work better in predicting tumor growth in patients with meningiom...
What is the current status of trial NCT03953131?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-01-10. Estimated completion is 2023-08-30.
What conditions does trial NCT03953131 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT03953131?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Gallium Ga 68-DOTATATE (RADIATION).
Who is sponsoring clinical trial NCT03953131?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03953131 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
RECRUITING · Phase 1
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.